



Durham Region Health Department FAX about...

For Health Care Professionals



Transition to Boostrix® & Pentacel® Vaccines

Transition from Adacel® to Boostrix®

Ontario's publicly funded Tdap vaccine is changing from Adacel® to **Boostrix®**. During the switchover period, you may receive either product based on stock availability and expiry dating. **Boostrix®** protects against diphtheria, tetanus, and pertussis. The Tdap vaccine is routinely given in Ontario to children 14-16 years of age.

Transition from Pediacel® to Pentacel®

Sanofi Vaccines Canada is discontinuing Pediacel® and will be transitioning to the **Pentacel®** vaccine. The formulation of these vaccines is nearly identical and fully interchangeable. **Pentacel®** (DTaP-IPV-Hib) is a combination vaccine for diphtheria, tetanus, acellular pertussis, inactivated polio, and haemophilus influenzae type b. The DTaP-IPV-Hib vaccine is routinely given in Ontario to children at 2, 4, 6 and 18 months of age.

Doses of Pediacel® can still be used until the expiration date.

Pentacel® will be included in orders after April 1st, 2024.

Pentacel® requires reconstitution. Refer to product monograph.

The packaging of Pentacel® is 5 single dose vials of Quadracel vaccine and 5 single dose vials of Hib lyophilized vaccine.



Since DTaP-IPV/Quadracel is no longer used in Ontario's publicly funded immunization schedule and was previously replaced by Tdap-IPV, the Pentacel® products should not be used as separate products (i.e., DTaP-IPV and Hib separately).

If you have any feedback about Fax Abouts or wish to recommend a topic for distribution, please email Faxabout@durham.ca.

March 20, 2024

905-668-2020 or 1-800-841-2729 | durham.ca/health

If you require this information in an accessible format, contact 1-800-841-2729.

